EMA
Following a review of disabling and potential long-term side effects of fluoroquinolone and quinolone antibiotics, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended a restriction of the use of these products. It concerns fluoroquinolone and quinolone antibiotics used by mouth, injection or inhalation. These restrictions include market withdrawal of quinolone containing antibiotics because they are authorised only for infections that should no longer be treated with this class of antibiotics, as well as a change of indication for fluoroquinolone antibiotics and extra safety precautions in certain cases.
More information can be found here.